Develop a safe and effective therapeutic to mitigate severe outcomes, including but not limited to mortality, in patients with severe infection or sepsis of any etiology.
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50121C00060
- Awardee
-
Bioaegis Therapeutics Inc. UEI G2AZAC2PG7X3
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $749,000
Award facts
- Opportunity
-
- BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement Solicitation · BAA20100SOL0002 · Posted Feb 3, 2020
- Contract value 100% obligated
- $749,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 10 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Morristown, NJ 07960, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $749,000 |
About this award
Bioaegis Therapeutics Inc. was awarded a $749,000 firm fixed price definitive contract by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to develop a safe and effective therapeutic to mitigate severe outcomes including mortality in patients with severe infection or sepsis of any etiology. This award was made under Special Instructions 019 to the department's Easy Broad Agency Announcement BAA-20-100-SOL-0002, which sought host-directed therapeutic candidates to aid long-term outcomes from lung injury through Area of Interest 12. The contract requires Bioaegis to pursue safety review of its recombinant human plasma gelsolin therapeutic through Phase I and share subsequent data and commercialization plans with the agency. No major subcontractors or set aside designations were identified.
Quick answers
Who was awarded contract 75A50121C00060?
75A50121C00060 was awarded to Bioaegis Therapeutics Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on June 11, 2021.
How much is contract 75A50121C00060 worth?
The government has obligated $749,000 on 75A50121C00060.
Was contract 75A50121C00060 competed?
The extent of competition for 75A50121C00060 was full and open competition. The government received 10 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award